P2Y <sub>12</sub> Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity
Michelle A. Berny‐Lang(Oregon Health & Science University), Andrew L. Frelinger(University of Nottingham), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Alan D. Michelson(Harvard University), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Marc R. Barnard
Cited by 19
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
|The Lancet|2009|723
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617